What Is 11-cis-retinol:NAD+ oxidoreductase

Overview

11-cis-retinol:NAD+ oxidoreductase is a crucial enzyme in the visual cycle, responsible for regenerating the chromophore necessary for vision in vertebrates. This enzyme catalyzes the oxidation of 11-cis-retinol to 11-cis-retinal, using NAD+ as a cofactor. Without this conversion, the visual pigment rhodopsin cannot be reformed after exposure to light, leading to impaired dark adaptation and night vision.

First identified in the retinal pigment epithelium (RPE) of the eye, this enzyme is encoded by the RDH5 gene, located on chromosome 12q24 in humans. The RDH5 gene was cloned and characterized in 1999, marking a significant advancement in understanding inherited retinal diseases. The enzyme belongs to the short-chain dehydrogenase/reductase (SDR) superfamily, which includes numerous enzymes involved in steroid, retinoid, and prostaglandin metabolism.

The significance of 11-cis-retinol:NAD+ oxidoreductase extends beyond basic vision physiology. Its dysfunction is directly linked to fundus albipunctatus, a rare form of congenital stationary night blindness first described by Georg Rüsse in 1905. Patients with mutations in RDH5 exhibit delayed dark adaptation and characteristic white dots in the retina. Understanding this enzyme’s function has therefore provided key insights into retinal biochemistry and potential therapeutic targets for retinal degenerations.

How It Works

The enzymatic mechanism of 11-cis-retinol:NAD+ oxidoreductase involves a precise biochemical transformation central to vision. The enzyme facilitates the transfer of a hydride ion from 11-cis-retinol to NAD+, forming NADH and 11-cis-retinal. This reaction is reversible under certain conditions, but in the physiological context of the RPE, it predominantly proceeds in the oxidative direction.

• Substrate Specificity: The enzyme shows high specificity for 11-cis-retinol, distinguishing it from other retinol dehydrogenases that act on all-trans isomers.
• Cofactor Requirement: It requires NAD+ as an electron acceptor, a characteristic feature of oxidoreductases in the SDR family.
• Reaction Type: It performs an oxidation reaction, converting a primary alcohol (retinol) into an aldehyde (retinal).
• Cellular Location: The enzyme is localized in the endoplasmic reticulum of retinal pigment epithelial cells.
• Enzyme Kinetics: Studies show a Km value of approximately 1.2 µM for 11-cis-retinol, indicating high substrate affinity.
• Protein Structure: It functions as a homodimer with each subunit weighing about 32 kDa.
• pH Optimum: The enzyme operates most efficiently at a slightly alkaline pH of 8.5–9.0, typical for retinal metabolic enzymes.

Key Details and Comparisons

The comparison highlights the specificity of 11-cis-retinol:NAD+ oxidoreductase in the visual cycle. While several enzymes can produce 11-cis-retinal, RDH5 is uniquely expressed in the RPE and is the primary enzyme responsible for chromophore regeneration under low-light conditions. Unlike RDH11, which is widely expressed but less efficient, RDH5 has evolved for high specificity and affinity. The tissue-specific expression patterns ensure compartmentalization of retinoid metabolism, preventing interference between visual and systemic retinoid pathways. Mutations in RDH5 do not affect embryonic development, underscoring its specialized role in postnatal vision.

Real-World Examples

In clinical settings, mutations in the RDH5 gene have been documented in multiple families worldwide, leading to the diagnosis of fundus albipunctatus. For instance, a 2004 study of a Japanese cohort identified a homozygous missense mutation (R100H) in affected individuals, confirming the enzyme's role in disease pathology. These patients exhibited prolonged dark adaptation times—sometimes exceeding 4 hours—compared to the normal 20–30 minutes. The white retinal dots, visible via fundoscopy, correlate with lipid-laden RPE cells, a hallmark of disrupted retinoid cycling.

Animal models have further validated the enzyme's function. Rdh5-knockout mice, developed in 2000, show delayed regeneration of rhodopsin and impaired recovery of retinal sensitivity after light exposure. These mice are used to test potential therapies, including synthetic retinoid analogs. The study of such models has also revealed compensatory mechanisms involving other dehydrogenases, though they are insufficient to fully restore vision.

1. A Japanese family with the R100H mutation in RDH5 showing classic fundus albipunctatus symptoms.
2. Rdh5-deficient mice exhibiting 80% slower rhodopsin regeneration compared to wild-type.
3. A Spanish patient cohort with compound heterozygous mutations identified in 2010.
4. Enzyme activity assays showing 95% reduction in RDH5 function in mutant variants.

Why It Matters

Understanding 11-cis-retinol:NAD+ oxidoreductase is vital for both basic science and clinical ophthalmology. Its role in the visual cycle makes it a cornerstone of retinal function, and its dysfunction reveals broader principles of metabolic compartmentalization in sensory tissues.

• Impact: Mutations cause fundus albipunctatus, affecting night vision and quality of life.
• Therapeutic Target: Enzyme replacement or pharmacological chaperones are being explored for RDH5-related disorders.
• Diagnostic Value: Genetic testing for RDH5 mutations allows early diagnosis and counseling.
• Research Tool: Knockout models help study retinoid metabolism and test new treatments.
• Evolutionary Insight: Conservation of RDH5 across vertebrates highlights its essential role in vision.

As research progresses, therapies targeting the visual cycle, including gene therapy for RDH5, may offer hope for patients with inherited retinal diseases. The enzyme exemplifies how molecular biology can illuminate both normal physiology and disease mechanisms.